Selected Publications
Valpione S, Galvani E, Tweedy J, Mundra PA, Banyard A, Middlehurst P, Barry J, Mills S, Salih Z, Weightman J, Gupta A, Gremel G, Baenke F, Dhomen N, Lorigan PC, Marais R. (2020)
Immune-awakening revealed by peripheral T cell dynamics after once cycle of immunotherapy.
Nature Cancer 1: 210-221. PubMed abstract
Galvani E, Mundra PA, Valpione S, Garcia-Martinez P, Smith M, Greenall J, Thakur R, Helmink B, Andrews MC, Boon L, Chester C, Gremel G, Hogan K, Mandal A, Zeng K, Banyard A, Ashton G, Cook M, Lorigan P, Wargo JA, Dhomen N, Marais R. (2020)
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma.
Nature Communications 11: 853. PubMed abstract
Trucco LD, Mundra PA, Hogan K, Garcia-Martinez P, Viros A, Mandal AK, Macagno N, Gaudy-Marqueste C, Allan D, Baenke F, Cook M, McManus C, Sanchez-Laorden B, Dhomen N, Marais R. (2019)
Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma.
Nature Medicine 25(2):221-224. PubMed abstract
Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn J, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R. (2018)
Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma.
Annals of Oncology 29(2):490-496. PubMed abstract
Tang H, Leung L, Saturno G, Viros A, Smith D, Di Leva G, Morrison E, Niculescu-Duvaz D, Lopes F, Johnson L, Dhomen N, Springer C, Marais R. (2017)
Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.
Nature Communications 8:14909. PubMed abstract
Gremel G, Lee RJ, Girotti MR, Mandal AK, Valpione S, Garner G, Ayub M, Wood S, Rothwell DG, Fusi A, Wallace A, Brady G, Dive C, Dhomen N, Lorigan P, Marais R. (2016)
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA.
Annals of Oncology 27(10):1959-65. PubMed abstract
Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N and Marais R. (2014)
Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
Nature 511(7510):478-82. PubMed abstract
Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno Neumann S, de la Grange P, Roman-Roman S, Stern M.-H., and Marais R. (2013)
SF3B1 mutations are associated with alternative splicing in uveal melanoma.
Cancer Discovery 3(10):1122-9. PubMed abstract
Su F, Viros A, Milagre C, Trunzer K, Bollag C, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Jung Kim M, Hayward F, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez F, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R. (2012)
RAS mutations in cutaneous squamous cell carcinomas with BRAF inhibitors.
The New England Journal of Medicine 366: 207-215. PubMed abstract